Business, energy, technology, markets and global industry news from Business News Today

venetoclax

PharmaDeviceNews venetoclax
Representative image: Hematology researchers analyze blood samples as Moleculin’s $MBRX MIRACLE trial reports a 37% blinded composite remission rate in relapsed or refractory acute myeloid leukemia, including patients who previously failed venetoclax.
Pharma & Biotech

New MIRACLE data examine remission after venetoclax failure in relapsed AML

MIRACLE reports a 37% blinded composite remission rate in relapsed AML, including patients who previously failed venetoclax treatment.

Read More
Representative image of hematology research and blood sample analysis, reflecting AbbVie’s long-term Venclexta data in first-line chronic lymphocytic leukemia treatment.
Pharma & Biotech

AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus

Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.

Read More
Pharma & Biotech

Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?

Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.

Read More
Pharma & Biotech

Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?

AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.

Read More